Mavenir Rated Very Strong in GlobalData's 2026 IMS and Voice Core Competitive Landscape Assessment

RICHARDSON, Texas, July 22, 2026 (GLOBE NEWSWIRE) — Mavenir, the software company building Telco-First, Cloud-Native, AI-by-design mobile networks, today announced that GlobalData has rated its MAVcore Cloud-Native IMS and Voice Services Very Strong in its IMS and Voice Core: Competitive Landscape Assessment (June 2026), placing Mavenir among the industry's top-rated IMS and Voice Core providers alongside Nokia, ZTE, and Ericsson.

The report evaluated vendors across five dimensions: solution architecture, platform and performance, feature and application support, interoperability, and deployment experience. MAVcore earned a Strong to Very Strong rating in all five.

Source: GlobalData, IMS and Voice Core Competitive Landscape Assessment, June, 2026.

Solution architecture: Very Strong. MAVcore was designed from the ground up as a Cloud-Native, microservices-based IMS purpose-built for VoLTE and 5G voice, with a single unified code base that eases migration from NFV-based deployments to fully containerized versions.

Platform and performance: Very Strong. The highly decomposed architecture scales independently by function, allowing operators to optimize resources per use case and adapt to shifting traffic patterns without degrading performance.

Interoperability: Very Strong. MAVcore delivers proven multi-vendor integration across policy, signaling, media, and device ecosystems, a critical requirement in the multivendor networks most operators run today.

Feature and application support: Strong. MAVcore delivers the core IMS features and supplementary services operators require for VoLTE and 5G voice deployments.

Deployment experience: Strong. Mavenir has grown its voice business to more than 50 customers worldwide, including high-profile greenfield deployments and voice transformation projects with established communications service providers (CSPs).

Beyond the five rated dimensions, GlobalData highlighted Mavenir's AI roadmap. Mavenir is focused on in-call AI services, including simultaneous translation, agentic SMB assistants, and transcription, targeting what GlobalData identifies as the fastest-growing voice service opportunity. Mavenir's signaling security, spam detection, and fraud management capabilities add a further layer of differentiation and a foundation for value-added services.

As voice calling evolves from human-to-human interaction to human-to-agent interaction, Mavenir will continue to invest in cloud-native architecture and AI-enabled services that help operators modernize their voice networks and capture new sources of revenue.

“Being recognized as Very Strong by GlobalData validates the investment Mavenir has made in cloud-native voice architecture,” said Sachin Karkala, EVP & General Manager, IMS & RAN, Mavenir. “As operators worldwide decommission legacy networks and look to monetize voice through AI-enabled services, Mavenir's ground-up cloud-native approach positions our customers to move faster and scale with confidence.”

“Mavenir designed its Cloud-Native IMS solution from the ground up for VoLTE and 5G voice,” said Andy Hicks, Senior Principal Analyst at GlobalData. “That architecture, and the company's base of more than 50 voice customers worldwide, are among the factors that earned Mavenir a Very Strong rating in this year's assessment.”

About Mavenir

Mavenir is enabling intelligent, automated, programmable networks through the development of telco-first, cloud-native, AI-by-design software solutions for mobile operators. The company's deep telco domain expertise has been proven through deployments with 300+ operators globally in over 120 countries, which together serve more than 50% of the world's subscribers. Mavenir combines its deep telco experience with the cloud and IT expertise and data science skillsets essential to solving real customer challenges. Its proven software solutions are AI by design, delivering the AI-native future and operators' evolution to TechCos. For more information, please visit www.mavenir.com

Media Contact:

Emmanuela Spiteri
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e640084-bb33-4433-baf4-c7d47f00ac15


GLOBENEWSWIRE (Distribution ID 9766171)

Die Society for Medical Decision Making ehrt UMIT TIROL- und Harvard-Professor Uwe Siebert mit dem „Career Achievement Award 2026“

OSLO, Norwegen, July 21, 2026 (GLOBE NEWSWIRE) — Die Society for Medical Decision Making (SMDM) verlieh ihre höchste Auszeichnung für das Lebenswerk, den 2026 Career Achievement Award, an Professor Uwe Siebert, MPH, MSc, ScD, von der UMIT TIROL und der Harvard University, in Anerkennung seiner jahrzehntelangen bahnbrechenden Beiträge zur medizinischen Entscheidungsfindung durch wegweisende Forschung, internationale Führungsarbeit, Lehre und Engagement.

Die Auszeichnung wurde im Rahmen der „Leadership Awards Session“ auf der 48. Jahrestagung der SMDM in Oslo, Norwegen, von Professor Mark Bounthavong, PharmD, PhD, Vorsitzender des SMDM-Auszeichnungskomitees und Professor für Klinische Pharmazie an der Skaggs School of Pharmacy and Pharmaceutical Sciences der University of California, San Diego, überreicht.

Mit dem SMDM Career Achievement Award werden herausragende leitende Wissenschaftlerinnen und Wissenschaftler gewürdigt, deren nachhaltige Beiträge die Wissenschaft und Praxis der medizinischen Entscheidungsfindung maßgeblich vorangebracht haben. Die Preisträgerinnen und Preisträger werden im Rahmen eines wettbewerbsorientierten Nominierungsverfahrens nach einer öffentlichen Ausschreibung ausgewählt und vom Preiskomitee der Fachgesellschaft bewertet.

„Es war mir eine große Ehre, Professor Uwe Siebert den Career Achievement Award 2026 der Society for Medical Decision Making zu überreichen“, sagte Professor Bounthavong. „Im Laufe seiner gesamten Laufbahn hat Professor Siebert die Werte verkörpert, die mit dieser Auszeichnung gewürdigt werden: wissenschaftliche Exzellenz, methodische Innovation, visionäre Führungsstärke und ein unerschütterliches Engagement für die Verbesserung von Entscheidungen im Gesundheitswesen auf der Grundlage fundierter wissenschaftlicher Evidenz. Seine Arbeit hat Forschende, Klinikerinnen und Kliniker, politische Entscheidungsträger sowie Generationen von Auszubildenden auf der ganzen Welt geprägt, weshalb er diese Anerkennung in besonderem Maße verdient hat.“

Professor Siebert ist Professor für Public Health, medizinische Entscheidungsfindung und Gesundheitstechnologiebewertung sowie Leiter des Instituts für Public Health, Medical Decision Making und Health Technology Assessment an der UMIT TIROL – Universität für Gesundheitswissenschaften und -technologie in Tirol, Österreich. Er ist zudem Adjunct Professor für Health Policy und Management sowie Epidemiologie an der Harvard T.H. Chan School of Public Health und affiliierter Forscher am Center for Health Technology Assessment am Mass General Brigham an der Harvard Medical School.

Als ausgebildeter Mediziner begann Professor Siebert seine berufliche Laufbahn mit der Mitarbeit in internationalen Public Health Projekten in Westafrika, Brasilien und Deutschland, bevor er sich in den Bereichen öffentliche Gesundheit, Epidemiologie und Entscheidungswissenschaften spezialisierte. Er erwarb seinen Magister in Public Health an der medizinischen Fakultät der Ludwig-Maximilians-Universität München sowie seinen Master of Science in Epidemiology und seinen Doctor of Science in Health Policy and Management an der Harvard School of Public Health.

Im Laufe von mehr als drei Jahrzehnten hat sich Professor Siebert zu einer der weltweit führenden Persönlichkeiten auf dem Gebiet der medizinischen Entscheidungswissenschaft entwickelt. Seine Pionierarbeit in den Bereichen medizinische Entscheidungsanalyse, Nutzen-Schaden-Abwägung, gesundheitsökonomische Evaluation, entscheidungsanalytische Modellierung, Bewertung von Gesundheitstechnologien, Epidemiologie und Kausalinferenz hat die evidenzbasierte Gesundheitsversorgung entscheidend vorangebracht und gleichzeitig weltweit direkten Einfluss auf klinische Leitlinien, Krebsfrüherkennungsprogramme, Health Technology Assessments, Erstattungsentscheidungen sowie nationale Gesundheitspolitik genommen.

Sein Einfluss reicht weit über die Forschung hinaus. Professor Siebert ist ehemaliger Präsident der SMDM und war zuletzt Präsident der ISPOR – The Professional Society for Health Economics and Outcomes Research. Im Laufe seiner Karriere beriet er Regierungsgremien, Health Technology Assessment Institutionen, Fachgesellschaften und internationale Gesundheitsorganisationen bei Fragen der evidenzbasierten Politikgestaltung und Entscheidungsfindung im Gesundheitswesen. Er ist Autor von mehr als 500 Publikationen, darunter wissenschaftliche Fachartikel, Lehrbuchkapitel, Policy Briefs und HTA-Berichte, und wirkt in leitenden Herausgeberfunktionen in mehreren international renommierten wissenschaftlichen Fachzeitschriften mit.

Professor Siebert engagiert sich zudem intensiv in der Lehre. Er hält Lehrveranstaltungen zu den Themen Heath Technology Assessment, Entscheidungswissenschaften und kausale Schlussfolgerungen aus Daten aus der Praxis im Rahmen des HTADS-Programms der UMIT TIROL sowie zum Thema Entscheidungsanalyse in der klinischen Forschung im Sommerprogramm der Harvard T.H. Chan School of Public Health.

In seiner Dankesrede würdigte Professor Siebert die Mentorinnen und Mentoren, Kolleginnen und Kollegen, Mitarbeitenden, Studierenden sowie Kooperationspartner, die seine Karriere geprägt haben, und betonte, dass wissenschaftlicher Fortschritt nicht allein auf Ideen beruhe, sondern vor allem auf den Menschen, die einander inspirieren, herausfordern und unterstützen.

„Ich fühle mich zutiefst geehrt, diese Auszeichnung entgegenzunehmen, und bin für diese besondere Anerkennung von Herzen dankbar“, so Professor Siebert. „Diese Auszeichnung würdigt nicht nur meine eigene Arbeit, sondern auch das Engagement und die Fachkompetenz meines gesamten Teams. Sie spiegelt zudem die Unterstützung, Ermutigung und Inspiration wider, die ich währen meiner gesamten Laufbahn von meinen Studierenden, Fellows, Mitarbeitenden, Mentorinnen und Mentoren, Freunden sowie meiner Familie erfahren durfte. Die SMDM war für mich eine außergewöhnliche intellektuelle Heimat, und ich bin dieser Gemeinschaft dankbar für die vielen Möglichkeiten, die sie mir geboten hat, zu lernen, zusammenzuarbeiten und mich weiterzuentwickeln.“

Einer der bewegendsten Momente in Professor Sieberts Rede war, als er über den tiefgreifenden Einfluss seines langjährigen Mentors Milton Weinstein, PhD, reflektierte, dessen Kurs an der Harvard University ihn erstmals mit der Entscheidungsanalyse vertraut machte und letztendlich die Richtung seiner wissenschaftlichen Laufbahn prägte. Professor Weinstein wurde 1996 mit dem „Career Achievement Award“ der SMDM ausgezeichnet, weshalb die Ehrung von Professor Siebert eine besondere Bedeutung erhält, da sie genau dreißig Jahre nach der Verleihung der höchsten Auszeichnung der Fachgesellschaft an seinen Mentor erfolgt.

„Karrieren entstehen nicht allein durch Ideen“, erklärte Professor Siebert in seiner Dankesrede, „sondern auch durch die Menschen, die uns inspirieren, an uns glauben und uns Türen öffnen.“

Während seiner Rede hob Professor Siebert die Bedeutung interdisziplinärer Zusammenarbeit sowie der engen Kooperation mit Entscheidungsträgern im Gesundheitswesen hervor, um Forschungsergebnisse in konkrete Verbesserungen der Patientenversorgung umzusetzen. Anhand von Beispielen aus seiner eigenen wissenschaftlichen Arbeit beschrieb er, wie die kollaborative Entscheidungsmodellierung nationale COVID-19-Impfstrategien und die Krebsfrüherkennungsprogramme unterstützt haben, und veranschaulichte damit, wie fundierte Entscheidungswissenschaft das Gesundheitswesen und die Gesundheit der Bevölkerung nachhaltig verbessern kann.

Abschließend ermutigte er die nächste Generation von Wissenschaftlerinnen und Wissenschaftlern, aktiv die Zusammenarbeit über Regionen und Fachgrenzen hinweg zu suchen und sich stets vor Augen zu halten, dass eine der wertvollsten Fähigkeiten in der Wissenschaft darin besteht, zuzuhören – den Kolleginnen und Kollegen, Patientinnen und Patienten, Entscheidungsträgern und im Team einander.

Mit dieser Auszeichnung reiht sich Professor Siebert in eine hochkarätige Gruppe von Preisträgerinnen und Preisträgern des „Career Achievement Award“ ein, deren Arbeit das Fachgebiet der medizinischen Entscheidungsfindung in den letzten drei Jahrzehnten maßgeblich geprägt und weiterentwickelt hat. Zu den bisherigen Preisträgern zählen Anne Stiggelbout, John B. Wong, Dawn Stacey, Michael Kattan, Doug Coyle, Karen Kuntz, Murray Krahn, M.G. Myriam Hunink, Valerie Reyna, Ivar Kristiansen, Alvin Mushlin, Mark Roberts, Donald Redelmeier, Annette O'Connor, Howard Raiffa, J. Sanford (Sandy) Schwartz, Alan Garber, Barbara J. McNeil, Peter Wakker, David J. Spiegelhalter, Allan Detsky, Joseph Pliskin, Jerome P. Kassirer, Daniel Kahneman, George Torrance, John Eisenberg, Dennis Fryback, Harold Sox, Arthur Elstein, Milton Weinstein und Stephen Pauker.

Über die Society for Medical Decision Making

Die 1979 gegründete Society for Medical Decision Making (SMDM) ist eine internationale wissenschaftliche Fachgesellschaft, die sich der Verbesserung der Gesundheit durch fundiertere Entscheidungsfindung im Gesundheitswesen verschrieben hat. Die Fachgesellschaft bringt Forschende, klinisch Tätige, Lehrende, politische Entscheidungsträger, Patientinnen und Patienten sowie führende Vertretende der Industrie zusammen, um die Wissenschaft und die Anwendung der medizinischen Entscheidungsfindung durch Forschung, Ausbildung, Zusammenarbeit und die Verbreitung evidenzbasierter Methoden voranzubringen.

Medienkontakt

Wendy Weber
Communications & Membership Director
Society for Medical Decision Making (SMDM)
[email protected]

Foto: Beate Jahn, PhD, SMDM-Präsidentin (2025–2026); Professor Uwe Siebert, MPH, MSc, ScD, Preisträger des SMDM Career Achievement Awards 2026; Mark Bounthavong, PharmD, PhD, Vorsitzender des SMDM-Auszeichnungskomitees; und Milton Weinstein, PhD, Preisträger des SMDM Career Achievement Awards 1996 und langjähriger Mentor von Professor Siebert, nach der Verleihung der höchsten SMDM-Auszeichnung für das Lebenswerk im Rahmen der 48. Jahrestagung der SMDM am 30. Juni 2026 in Oslo, Norwegen.

Ein Foto zu dieser Mitteilung finden Sie unter https://www.globenewswire.com/NewsRoom/AttachmentNg/ab9069d2-20fe-42ae-a183-4edaa2638c4d


GLOBENEWSWIRE (Distribution ID 9765875)

WeRide Named Among China's Top 10 AI Case Studies for UAE Autonomous Driving Deployment, the Only Autonomous Driving Company Recognized

SHANGHAI, July 17, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced that its autonomous driving deployment in the United Arab Emirates (UAE) has been selected as one of the Top 10 examples of international cooperation in Chinese AI technologies and products in AI From China Benefits the World (2026), in a national case collection released at the 2026 World Artificial Intelligence Conference (WAIC).

WeRide was the only autonomous driving company included on the list, with its UAE operations recognized as a benchmark for the international deployment of Chinese AI innovation. This underscores the growing global impact of autonomous mobility and demonstrates how Chinese autonomous driving technologies can be successfully deployed, regulated and commercialized in international markets.

Officials release AI From China Benefits the World (2026)

during the main forum of WAIC 2026 in Shanghai

The recognition was announced at the main forum of WAIC 2026, where China's National Development and Reform Commission (NDRC) released AI From China Benefits the World (2026). Since 2024, the initiative has highlighted impactful AI cooperation projects that demonstrate how Chinese technologies deliver meaningful social and economic value globally.

Today, WeRide's fully driverless Robotaxi services have become part of daily transportation in the UAE. The company operates commercial Robotaxi services in both Abu Dhabi and Dubai, with riders able to access the service through the Uber platform. WeRide is currently the only company outside the United States providing fully driverless Robotaxi services on Uber.

The company's achievements in the UAE are the result of years of continuous deployment and collaboration with local stakeholders. WeRide began public Robotaxi operations in Abu Dhabi in 2021, becoming one of the first autonomous driving companies to establish services in the country and establishing a four-year first-mover advantage in the market.

Since then, the company has continued to achieve key regulatory and commercial milestones with its extensive operational track record and proven technology. In 2023, WeRide became the first company to receive the UAE's national license for self-driving vehicles, authorizing autonomous vehicle testing and operation on public roads nationwide, subject to local approvals. In December 2024, WeRide and Uber launched the largest commercial Robotaxi service outside the United States and China in Abu Dhabi.

Operations continued to expand in October 2025, as WeRide expanded its Robotaxi services to Ras Al Khaimah, bringing its operations to a third emirate in the UAE. One month later, WeRide became the first company to launch fully driverless commercial Robotaxi services in Abu Dhabi, enabled by the world's first city-level L4 autonomous driving commercial permit issued outside the United States.

Today, WeRide's Robotaxi network covers approximately 70% of Abu Dhabi's core urban areas, with operations spanning Abu Dhabi, Dubai and Ras Al Khaimah.

WeRide's progress in commercial deployment aligns closely with the UAE's long-term transportation strategy. As Dubai works towards 25% of all transportation journeys to be autonomous by 2030, and Abu Dhabi advances plans to significantly increase the share of autonomous mobility in the coming decades, the regular operation of WeRide's Robotaxi services provide practical support for the UAE in improving transportation efficiency and advancing its smart mobility transformation.

With its UAE deployment serving as a benchmark, WeRide has developed a comprehensive global operating model spanning technology adaptation, regulatory engagement and commercial operations, to enable the integration of autonomous driving into urban transportation systems across diverse markets. Beyond the UAE, WeRide has launched public Robotaxi services in Riyadh and Singapore, while expanding into additional international markets including Madrid and Zurich, further strengthening its global presence across multiple regions, vehicle platforms and deployment scenarios.

Today, WeRide's autonomous driving products have a presence in more than 40 cities across 12 countries. The company holds autonomous driving permits in eight countries and operates a global Level 4 autonomous driving fleet of over 3,000 vehicles.

From the UAE to an expanding number of markets globally, WeRide continues to demonstrate how autonomous driving can be safely deployed, commercially operated and integrated into urban transportation systems worldwide. The company remains committed to advancing the global adoption of autonomous mobility and creating long-term value for cities, passengers and industry partners.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 12 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's 2025 Change the World and 2025 Future 50 lists.

Media Contacts

[email protected]

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/11d8420c-0599-4295-bf75-96ec4b0be058


GLOBENEWSWIRE (Distribution ID 9764305)

Society for Medical Decision Making Homenageia Professor Uwe Siebert da UMIT TIROL e da Harvard com Prêmio de Realização de Carreira de 2026

OSLO, Noruega, July 17, 2026 (GLOBE NEWSWIRE) — A Society for Medical Decision Making (SMDM) entregou sua maior homenagem a carreiras, o 2026 Career Achievement Award, ao professor Uwe Siebert, MPH, MSc, ScD, da UMIT TIROL e da Harvard University, reconhecendo suas décadas de contribuições transformadoras para a tomada de decisões médicas por meio de pesquisas inovadoras, liderança internacional, educação e serviço.

O prêmio foi entregue durante a Sessão de Premiação de Liderança na SMDM 48th Annual Meeting em Oslo, Noruega, pelo Professor Mark Bounthavong, PharmD, PhD, Presidente do Comitê de Premiação da SMDM e Professor de Farmácia Clínica da Skaggs School of Pharmacy and Pharmaceutical Sciences da University of California, San Diego.

O Prêmio SMDM de Realização de Carreira reconhece pesquisadores seniores de destaque cujas contribuições contínuas têm promovido avanços significativos na ciência e na prática de tomadas de decisão médica. Os premiados são selecionados por meio de um processo de nomeação competitivo após uma chamada aberta e são avaliados pelo Comitê de Premiação da Sociedade.

“Foi uma grande honra entregar o Prêmio de Realização de Carreira 2026 da Society for Medical Decision Making ao Professor Uwe Siebert”, disse o Professor Bounthavong. “Ao longo da sua carreira, o professor Siebert tem sido um exemplo das qualidades que este prêmio representa, excelência científica, inovação metodológica, liderança visionária e compromisso inabalável com o aprimoramento das decisões de saúde com base em sólidas evidências. O trabalho dele influencia pesquisadores, médicos, formuladores de políticas e gerações de estagiários em todo o mundo. Ele é excepcionalmente merecedor dessa homenagem.”

O Professor Siebert é Professor de Saúde Pública, Tomada de Decisão Médica e Avaliação de Tecnologias de Saúde e Chefe do Institute of Public Health, Medical Decision Making and Health Technology Assessment da UMIT TIROL – University for Health Sciences and Health Technology na Áustria. Ele também é Professor Adjunto de Política e Gestão de Saúde e Epidemiologia, da Harvard T.H. Chan School of Public Health e pesquisador afiliado do Center for Health Technology Assessment da Mass General Brigham, Harvard Medical School.

Médico de formação, o professor Siebert iniciou sua carreira trabalhando em projetos internacionais de saúde pública na África Ocidental, Brasil e Alemanha antes de buscar treinamento em saúde pública, epidemiologia e ciências da decisão. Ele obteve seu mestrado em Saúde Pública na Munich School of Public Health and Epidemiology e mestrado em Epidemiologia e doutorado em Política e Gestão em Saúde na Harvard School of Public Health.

Ao longo de mais de três décadas, o professor Siebert tornou-se uma das principais vozes do mundo na tomada de decisões médicas. Seu trabalho pioneiro em análise de decisões médicas, avaliação de benefícios e danos, avaliação econômica da saúde, modelagem analítica de decisões, avaliação de tecnologias de saúde, epidemiologia e inferência causal avançou a ciência dos cuidados de saúde com base em evidências, ao mesmo tempo em que informou diretamente diretrizes clínicas, programas de rastreamento de câncer, avaliações de tecnologias de saúde, decisões de reembolso, e políticas nacionais de saúde em todo o mundo.

Sua influência se estende muito além da área de pesquisa. O professor Siebert é ex-presidente da SMDM e atua como recente ex-presidente da ISPOR – The Professional Society for Health Economics and Outcomes Research. Ao longo da sua carreira, ele aconselhou governos, agências de avaliação de tecnologias em saúde, sociedades profissionais e organizações internacionais sobre políticas com base em evidências e tomada de decisões em saúde. Ele é autor de mais de 500 publicações, incluindo artigos científicos, capítulos de livros didáticos, resumos de políticas e relatórios de ATS, e atua em funções de liderança editorial de várias revistas científicas reconhecidas internacionalmente.

O professor Siebert também é um educador dedicado, ministrando cursos de avaliação de tecnologias de saúde, ciências da decisão e inferência causal a partir de dados do mundo real no HTADS Program da UMIT TIROL e Decision Analysis in Clinical Research no programa de verão da Harvard T.H. Chan School of Public Health.

Ao aceitar o prêmio, o professor Siebert falou sobre os mentores, colegas, alunos e colaboradores que moldaram sua carreira, enfatizando que o avanço científico é construído não apenas com ideias, e sim com as pessoas que se inspiram, desafiam e apoiam umas às outras.

“Estou profundamente honrado em receber este prêmio e verdadeiramente grato por este reconhecimento especial”, disse o professor Siebert. “Este prêmio reflete não apenas o meu próprio trabalho, mas também a dedicação e a competência de toda a minha equipe. Também reflete o apoio, o incentivo e a inspiração que recebi ao longo da minha carreira de meus alunos, companheiros, colegas, mentores, amigos e minha família. A SMDM tem sido uma casa intelectual extraordinária, e sou grato a esta comunidade pelas oportunidades que me deu para aprender, colaborar e crescer.”

Um dos momentos mais comoventes do discurso do professor Siebert ocorreu quando ele falou sobre a profunda influência do seu mentor de longa data, Milton Weinstein, PhD, cujo curso de Harvard o apresentou pela primeira vez à análise de decisões e, finalmente, moldou a direção da sua carreira. O Professor Weinstein recebeu o Prêmio de Realização de Carreira da SMDM em 1996, tornando o reconhecimento do Professor Siebert especialmente significativo, pois ocorre exatamente trinta anos depois que seu mentor recebeu a mais alta honra da Sociedade.

“As carreiras são construídas não apenas com base em ideias”, refletiu o professor Siebert durante seu discurso de aceitação, “mas também com base nas pessoas que nos inspiram, acreditam em nós e abrem portas”.

Ao longo do seu discurso, o professor Siebert destacou a importância da colaboração interdisciplinar e do trabalho direto com os tomadores de decisão de saúde para traduzir a pesquisa em melhorias significativas no atendimento ao paciente. Com base em exemplos da sua própria carreira, ele descreveu como a modelagem da decisão colaborativa informou as estratégias nacionais de vacinação contra a COVID-19 e as políticas de rastreamento do câncer, ilustrando como a ciência de decisão rigorosa pode ter um impacto duradouro nos sistemas de saúde e na saúde da população.

Ele concluiu incentivando a próxima geração de pesquisadores a abraçar a colaboração entre regiões e disciplinas e a lembrar que uma das habilidades mais valiosas da ciência é ouvir colegas, pacientes, tomadores de decisão e uns aos outros.

O professor Siebert passa a fazer parte de um grupo distinto de premiados do Career Achievement Award, cujo trabalho tem definido e avançado no campo da tomada de decisões médicas nas últimas três décadas. Os homenageados anteriores incluem Anne Stiggelbout, John B. Wong, Dawn Stacey, Michael Kattan, Doug Coyle, Karen Kuntz, Murray Krahn, M.G. Myriam Hunink, Valerie Reyna, Ivar Kristiansen, Alvin Mushlin, Mark Roberts, Donald Redelmeier, Annette O'Connor, Howard Raiffa, J. Sanford (Sandy) Schwartz, Alan Garber, Barbara J. McNeil, Peter Wakker, David J. Spiegelhalter, Allan Detsky, Joseph Pliskin, Jerome P. Kassirer, Daniel Kahneman, George Torrance, John Eisenberg, Dennis Fryback, Harold Sox, Arthur Elstein, Milton Weinstein, e Stephen Pauker.

Sobre a Society for Medical Decision Making

Fundada em 1979, a Society for Medical Decision Making (SMDM) é uma organização profissional internacional dedicada a aprimorar os resultados de saúde por meio de uma melhor tomada de decisão. A Sociedade reúne pesquisadores, médicos, educadores, formuladores de políticas, pacientes e líderes do setor para promover a ciência e a aplicação da tomada de decisões médicas por meio da pesquisa, educação, colaboração e disseminação de métodos com base em evidências.

Contato com a Mídia

Wendy Weber
Diretora de Comunicações e Associação
Society for Medical Decision Making (SMDM)
[email protected]

Foto: Beate Jahn, PhD, Presidente da SMDM (2025–2026); Professor Uwe Siebert, MPH, MSc, ScD, premiado com o 2026 SMDM Career Achievement Award; Mark Bounthavong, PharmD, PhD, Presidente do SMDM Awards Committee; e Milton Weinstein, PhD, premiado com o 1996 SMDM Career Achievement Award e mentor de longa data do Professor Siebert, após a apresentação da maior honra de carreira da SMDM durante a 48ª Reunião Anual da SMDM em Oslo, Noruega, em 30 de junho de 2026.

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/ab9069d2-20fe-42ae-a183-4edaa2638c4d


GLOBENEWSWIRE (Distribution ID 9764302)

La Society for Medical Decision Making décerne le 2026 Career Achievement Award à Uwe Siebert, professeur à Harvard et à UMIT TIROL

OSLO, Norvège, 18 juill. 2026 (GLOBE NEWSWIRE) — La Society for Medical Decision Making (SMDM) a remis sa distinction professionnelle la plus prestigieuse, le 2026 Career Achievement Award, au professeur Uwe Siebert, MPH, MSc, ScD de UMIT TIROL et l’université Harvard, qui reconnaît ses décennies de contributions transformatrices à travers de la recherche innovante, un leadership international, l’enseignement et des services.

Cette récompense a été décernée lors de la remise du Leadership Award à l’occasion de la 48e réunion annuelle de la SMDM d’Oslo, en Norvège, par le professeur Mark Bounthavong, PharmD, PhD, président du SMDM Awards Committee et professeur de pharmacie clinique à la Skaggs School of Pharmacy and Pharmaceutical Sciences de l’Université de Californie de San Diego.

Le SMDM Career Achievement Award reconnaît les éminents investigateurs seniors dont les contributions soutenues ont font progresser de manière significative la science et la pratique de la prise de décision médicale. Les récipiendaires sont sélectionnés grâce à un processus de nomination compétitif, faisant suite à un appel à candidatures ouvert et sont évalués par le Awards Committee de la Society.

« C’était un immense honneur de décerner le Career Achievement Award de 2026 de la Society for Medical Decision Making à Uwe Siebert, professeur à Harvard » a déclaré le professeur Bounthavong. « Tout au long de sa carrière, le professeur Siebert a démontré les qualités célébrées par ce prix, à savoir l’excellence scientifique, l’innovation méthodologique, le leadership visionnaire et un engagement sans faille dans l’amélioration des décisions en matière de soins de santé grâce à des démonstrations rigoureuses. Son travail a influencé des chercheurs, des cliniciens, des décideurs politiques et des générations de stagiaires du monde entier, le rendant exceptionnellement digne d’être ainsi reconnu. »

Le professeur Siebert occupe le poste de professeur de santé publique, de prise de décision médicale et d’évaluation de technologie de santé, et de responsable de l’Institute of Public Health, Medical Decision Making and Health Technology Assessment à l’université UMIT TIROL, université des sciences médicales et de la technologie médicale en Autriche. Il est également professeur adjoint de politique et gestion de sant, et d’épidémiologie à la Harvard T.H. Chan School of Public Health, et chercheur affilié au Center for Health Technology Assessment de Mass General Brigham, Harvard Medical School.

Formé en tant que médecin, le professeur Siebert a débuté sa carrière en travaillant sur des projets de santé publique internationaux en Afrique occidentale, au Brésil et en Allemagne, avant de poursuivre une formation dans les sciences de santé publique, épidémiologie et prise de décision. Il a obtenu son master de santé publique à la Munich School of Public Health and Epidemiology et son master de science de l’épidémiologie, ainsi que son doctorat en sciences, politique et gestion de la santé à la Harvard School of Public Health.

Pendant plus de trois décennies, le professeur Siebert est devenu l’une des voix les plus influentes au monde en matière de prise de décision médicale. Son travail pionnier dans l’analyse de la décision médicale, l’évaluation des bénéfices-risques, l’évaluation de la santé dans un contexte économique, le modelage de l’analyse de décision, l’évaluation de la technologie en matière de santé, l’épidémiologie et l’inférence causale a fait progresser la science des soins de santé basés sur des preuves tout en éclairant les directives cliniques, les programmes de détection du cancer, les évaluations de technologie de santé, les décisions de remboursement et les politiques en matière de santé nationales dans le monde entier.

Son influence s’étend bien au-delà de la recherche. Le professeur Siebert est un ancien président de la SMDM et occupe le poste d’ancien président récent de la ISPOR – The Professional Society for Health Economics and Outcomes Research. Tout au long de sa carrière, il a conseillé des gouvernements, des agences d’évaluation de technologie de santé, des sociétés professionnelles et des organismes internationaux dans les politiques basées sur des preuves et dans la prise de décision en soins de santé. Il est l’auteur de plus de 500 publications, y compris des articles scientifiques, des chapitres de manuels, des synthèses de politique publique et des rapports du HTA, et occupe des postes de leadership éditorial pour plusieurs revues scientifiques mondialement reconnues.

Le professeur Siebert est également un pédagogue engagé qui enseigne l’évaluation des technologies de santé, les sciences décisionnelles et l’inférence causale basée sur des données réelles dans le cadre du HTADS Program à UMIT TIROL et la Decision Analysis in Clinical Research dans le cadre du programme estival de la Harvard T.H. Chan School of Public Health.

En recevant son prix, le professeur Siebert a partagé sa réflexion sur les maîtres, collègues, étudiants et collaborateurs qui ont façonné sa carrière et a souligné que les progrès scientifiques se fondent non seulement sur des idées, mais s’appuient également sur les personnes qui inspirent, relèvent des défis et se soutiennent mutuellement.

« Je suis profondément honoré de recevoir ce prix et suis reconnaissant de cette distinction spéciale » a commenté le professeur Siebert. « Ce prix reflète non seulement mon travail personnel, mais aussi l’engagement et l’expertise de toute mon équipe. Il reflète également le soutien, les encouragements et l’inspiration que j’ai reçus de la part de mes étudiants, pairs, collègues, maîtres, amis et famille tout au long de ma carrière. J’ai toujours considéré la SMDM comme une extraordinaire communauté de pensée et lui suis reconnaissant pour les opportunités qu’elle m’a offertes d’apprendre, collaborer et de grandir. »

L’un des propos les plus poignants du professeur Siebert présentait sa réflexion sur l’influence profonde de son maître de longue date, Milton Weinstein, PhD, dont les cours à Harvard l’ont initié à l’analyse décisionnelle, façonnant la direction définitive de sa carrière. Le professeur Weinstein a reçu le Career Achievement Award de la SMDM en 1996, créant une symbolique d'autant plus forte pour le prix du professeur Siebert, reçu exactement trente ans après que son maître ait obtenu le prix le plus prestigieux de la Society.

Lors de son discours de remerciement, le professeur Siebert a élaboré la réflexion suivante : « Une carrière se fonde sur des idées, mais s’appuie également sur les personnes qui nous inspirent, croient en nous et favorisent des avancées. »

Tout au long de son discours, le professeur Siebert a souligné l’importance de la collaboration interdisciplinaire et de travailler directement avec les décisionnaires du monde de la santé pour transformer la recherche en améliorations significatives pour les soins aux patients. En s’appuyant sur des exemples tirés de sa propre carrière, il a décrit à quel point le modelage de la décision collaborative a éclairé les stratégies de vaccination de la COVID-19 et les recommandations de détection du cancer, illustrant combien une science décisionnelle rigoureuse peut avoir un impact durable sur les systèmes de soins de santé et la santé des populations.

Il a conclu en encourageant la génération suivante de chercheurs à adopter pleinement la collaboration à travers les régions et les disciplines, et à se rappeler que l’une des compétences les plus valables de la science est d’écouter les collègues, les patients, les décideurs et l’écoute mutuelle en général.

Le professeur Siebert rejoint un groupe prestigieux de récipiendaires d’un Career Achievement Award, dont le travail a façonné et fait progresser le champ de la prise décisionnelle médicale au cours des trois dernières décennies. Les précédents lauréats comprennent : Anne Stiggelbout, John B. Wong, Dawn Stacey, Michael Kattan, Doug Coyle, Karen Kuntz, Murray Krahn, M.G. Myriam Hunink, Valerie Reyna, Ivar Kristiansen, Alvin Mushlin, Mark Roberts, Donald Redelmeier, Annette O’Connor, Howard Raiffa, J. Sanford (Sandy) Schwartz, Alan Garber, Barbara J. McNeil, Peter Wakker, David J. Spiegelhalter, Allan Detsky, Joseph Pliskin, Jerome P. Kassirer, Daniel Kahneman, George Torrance, John Eisenberg, Dennis Fryback, Harold Sox, Arthur Elstein, Milton Weinstein et Stephen Pauker.

À propos de la Society for Medical Decision Making

Fondée en 1979, la Society for Medical Decision Making (SMDM) est une organisation professionnelle internationale qui s’engage pour l’amélioration des résultats de santé par de meilleures prises décisionnelles. La Société réunit des chercheurs, des cliniciens, des pédagogues, des responsables politiques, des patients et des leaders d’industrie pour faire progresser la science et l’application des prises de décision médicales grâce à la recherche, la formation, la collaboration et la dissémination des méthodes basées sur des preuves.

Contact presse

Wendy Weber
Communications & Membership Director
Society for Medical Decision Making (SMDM)
[email protected]

Photo : Beate Jahn, PhD, Présidente de la SMDM (2025–2026) ; Professeur Uwe Siebert, MPH, MSc, ScD, lauréat du 2026 SMDM Career Achievement Award ; Mark Bounthavong, PharmD, PhD, président du SMDM Awards Committee ; et Milton Weinstein, PhD, lauréat du 1996 SMDM Career Achievement Award et maître de longue date du professeur Siebert, à la suite de la remise de la plus prestigieuse distinction professionnelle de la SMDM lors de la 48e réunion annuelle de la SMDM à Oslo, en Norvège le 30 juin 2026.

Une photo accompagnant cette annonce est disponible à l'adresse suivante :https://www.globenewswire.com/NewsRoom/AttachmentNg/ab9069d2-20fe-42ae-a183-4edaa2638c4d


GLOBENEWSWIRE (Distribution ID 9764302)

Society for Medical Decision Making Honors UMIT TIROL and Harvard Professor Uwe Siebert with 2026 Career Achievement Award

OSLO, Norway, July 16, 2026 (GLOBE NEWSWIRE) — The Society for Medical Decision Making (SMDM) presented its highest career honor, the 2026 Career Achievement Award, to Professor Uwe Siebert, MPH, MSc, ScD, of UMIT TIROL and Harvard University, recognizing his decades of transformative contributions to medical decision making through groundbreaking research, international leadership, education, and service.

The award was presented during the Leadership Awards Session at the SMDM 48th Annual Meeting in Oslo, Norway, by Professor Mark Bounthavong, PharmD, PhD, Chair of the SMDM Awards Committee and Professor of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego.

The SMDM Career Achievement Award recognizes distinguished senior investigators whose sustained contributions have significantly advanced the science and practice of medical decision making. Recipients are selected through a competitive nomination process following an open call and are evaluated by the Society's Awards Committee.

“It was a tremendous honor to present the Society for Medical Decision Making's 2026 Career Achievement Award to Professor Uwe Siebert,” said Professor Bounthavong. “Throughout his career, Professor Siebert has exemplified the qualities this award celebrates, scientific excellence, methodological innovation, visionary leadership, and an unwavering commitment to improving healthcare decisions through rigorous evidence. His work has influenced researchers, clinicians, policymakers, and generations of trainees around the world, making him exceptionally deserving of this recognition.”

Professor Siebert serves as Professor of Public Health, Medical Decision Making and Health Technology Assessment and Head of the Institute of Public Health, Medical Decision Making and Health Technology Assessment at UMIT TIROL – University for Health Sciences and Health Technology in Austria. He is also Adjunct Professor of Health Policy and Management, and Epidemiology, at the Harvard T.H. Chan School of Public Health, and an affiliated researcher at the Center for Health Technology Assessment at Mass General Brigham, Harvard Medical School.

A physician by training, Professor Siebert began his career working in international public health projects in West Africa, Brazil, and Germany before pursuing training in public health, epidemiology, and decision sciences. He earned his Master of Public Health from the Munich School of Public Health and Epidemiology and both his Master of Science in Epidemiology and Doctor of Science in Health Policy and Management from the Harvard School of Public Health.

Over more than three decades, Professor Siebert has become one of the world's leading voices in medical decision making. His pioneering work in medical decision analysis, benefit-harm assessment, health-economic evaluation, decision-analytic modeling, health technology assessment, epidemiology, and causal inference has advanced the science of evidence-based healthcare while directly informing clinical guidelines, cancer screening programs, health technology assessments, reimbursement decisions, and national health policies around the world.

His influence extends well beyond research. Professor Siebert is a Past President of SMDM and serves as recent Past President of ISPOR – The Professional Society for Health Economics and Outcomes Research. Throughout his career, he has advised governments, health technology assessment agencies, professional societies, and international organizations on evidence-based policy and healthcare decision making. He has authored more than 500 publications, including scientific articles, textbook chapters, policy briefs, and HTA reports, and serves in editorial leadership roles for several internationally recognized scientific journals.

Professor Siebert is also a dedicated educator, teaching courses in health technology assessment, decision sciences, and causal inference from real-world data at the HTADS Program at UMIT TIROL and Decision Analysis in Clinical Research in the summer program at the Harvard T.H. Chan School of Public Health.

Accepting the award, Professor Siebert reflected on the mentors, colleagues, students, and collaborators who shaped his career, emphasizing that scientific advancement is built not only on ideas but on the people who inspire, challenge, and support one another.

“I am deeply honored to receive this award, and I am truly grateful for this special recognition,” said Professor Siebert. “This award reflects not only my own work but also the dedication and expertise of my entire team. It also reflects the support, encouragement, and inspiration I have received throughout my career from my students, fellows, colleagues, mentors, friends, and my family. SMDM has been an extraordinary intellectual home, and I am grateful to this community for the opportunities it has given me to learn, collaborate, and grow.”

One of the most poignant moments of Professor Siebert's remarks came as he reflected on the profound influence of his longtime mentor, Milton Weinstein, PhD, whose Harvard course first introduced him to decision analysis and ultimately shaped the direction of his career. Professor Weinstein received SMDM's Career Achievement Award in 1996, making Professor Siebert's recognition especially meaningful as it comes exactly thirty years after his mentor received the Society's highest honor.

“Careers are built not only on ideas,” Professor Siebert reflected during his acceptance remarks, “but also on the people who inspire us, believe in us, and open doors.”

Throughout his address, Professor Siebert highlighted the importance of interdisciplinary collaboration and working directly with healthcare decision-makers to translate research into meaningful improvements in patient care. Drawing on examples from his own career, he described how collaborative decision modeling informed national COVID-19 vaccination strategies and cancer screening policies, illustrating how rigorous decision science can have a lasting impact on healthcare systems and population health.

He concluded by encouraging the next generation of researchers to embrace collaboration across regions and disciplines and to remember that one of the most valuable skills in science is listening, to colleagues, patients, decision-makers, and one another.

Professor Siebert joins a distinguished group of Career Achievement Award recipients whose work has defined and advanced the field of medical decision making over the past three decades. Previous honorees include Anne Stiggelbout, John B. Wong, Dawn Stacey, Michael Kattan, Doug Coyle, Karen Kuntz, Murray Krahn, M.G. Myriam Hunink, Valerie Reyna, Ivar Kristiansen, Alvin Mushlin, Mark Roberts, Donald Redelmeier, Annette O'Connor, Howard Raiffa, J. Sanford (Sandy) Schwartz, Alan Garber, Barbara J. McNeil, Peter Wakker, David J. Spiegelhalter, Allan Detsky, Joseph Pliskin, Jerome P. Kassirer, Daniel Kahneman, George Torrance, John Eisenberg, Dennis Fryback, Harold Sox, Arthur Elstein, Milton Weinstein, and Stephen Pauker.

About the Society for Medical Decision Making

Founded in 1979, the Society for Medical Decision Making (SMDM) is an international professional organization dedicated to improving health outcomes through better decision making. The Society brings together researchers, clinicians, educators, policymakers, patients, and industry leaders to advance the science and application of medical decision making through research, education, collaboration, and the dissemination of evidence-based methods.

Media Contact

Wendy Weber
Communications & Membership Director
Society for Medical Decision Making (SMDM)
[email protected]

Photo: Beate Jahn, PhD, SMDM President (2025–2026); Professor Uwe Siebert, MPH, MSc, ScD, recipient of the 2026 SMDM Career Achievement Award; Mark Bounthavong, PharmD, PhD, Chair of the SMDM Awards Committee; and Milton Weinstein, PhD, recipient of the 1996 SMDM Career Achievement Award and Professor Siebert's longtime mentor, following the presentation of SMDM's highest career honor during the SMDM 48th Annual Meeting in Oslo, Norway, on June 30, 2026.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab9069d2-20fe-42ae-a183-4edaa2638c4d


GLOBENEWSWIRE (Distribution ID 9763537)